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Hypertension is one of the most common human disorders, affecting ~26% of the adult 21 population worldwide(9). Half of all strokes and ischemic heart disease events are attributable to 22 high blood pressure (BP). It has been well reported that the cardiovascular response to exercise is 23 exaggerated in hypertensive patients and characterized by augmented increases in arterial BP, 24 heart rate (HR), and sympathetic nerve activity (SNA)(1; 17; 19; 27). Considering that these 25 patients already have high BP, the exaggerated exercise-evoked sympathetic and pressor 26 responses could further increase the risk for adverse cardiovascular or cerebrovascular events 27 including myocardial ischemia, myocardial infarction, cardiac arrest and/or stroke during or 28
immediately following a bout of exercise. Therefore, it is extremely important to understand the 29 potential mechanisms underlying the exaggerated cardiovascular response to exercise in 30 hypertension. In the past decade, a series of studies from Smith and colleagues have made 31 significant contributions to this field. In general, evidence from their laboratory suggest that an 32 overactive exercise pressor reflex (EPR), a peripheral neural reflex originating in skeletal 33 muscle, contributes to this abnormal cardiovascular responsiveness during exercise in several 34 hypertensive rodent models (11; 14; 15; 24). The afferent arm of this reflex is composed of both 35 metabolically sensitive (group IV, C) and mechanically sensitive (group III, Aδ) fibers (7; 8). While this finding appears inconsistent with that described in the SHR and PPH 50 models, this discrepancy may be due to several factors including 1) the different animal models 51 (rats vs. canines); 2) exercise paradigms (static contraction vs. submaximal dynamic exercise); 3) 52 surgical preparation (decerebration vs. conscious). A major difference is the preparation and the 53 mechanisms mediating the pressor responses. It is highly likely that in the decerebrated rat 54 preparation the rise in BP with the EPR is entirely due to peripheral vasoconstriction which is 55 exaggerated in SHR. In contrast, in dogs, the rise in BP is almost entirely due to increases in 56 cardiac output. In the study by Spranger et al. (25) , the authors concluded that there was a shift 57 towards more vasoconstriction in hypertension inasmuch as the normal vasodilation (likely due 58 to epinephrine release) was attenuated. So, both preparations would support enhanced peripheral 59 vasoconstriction in response to exercise in hypertension. Further studies should be carried out to 60 address this discrepancy. 61
In the current paper(3), Downey et al. further attempted to address the potential mechanism 62 underlying the exaggerated EPR in SHR rats. They examined the effects of mineralocorticoid 63 receptor (MR) antagonists (spironolactone, SPIR; eplerenone, EPL) on the EPR in both WKY 64 and SHR rats. The authors used static contraction to activate the EPR whereas muscle passive 65 stretch was used to selectively activate the mechanoreflex. The primary finding of this study is 66 that both chronic SPIR and EPL administration attenuated the exaggerated EPR as well as the 67 mechanoreflex in SHR rats whereas they had no effect in the normotensive WKY rats. 68
Generally, this study suggests that MR/aldosterone signaling plays a critical role in mediating the 69 exaggerated EPR in the hypertensive rather than normotensive states. A potential limitation of 70 this study is that the authors did not verify the effective target of mineralocorticoid antagonists 71 (central vs. peripheral). It is possible that single/multiple components of the EPR reflex arc 72 including sensory afferents, the spinal cord or cardiovascular regions in the brain stem could be 73 affected by this systemic administration. In conclusion, the current paper by Downey and colleagues (3) discovered a novel role of 107 MR/aldosterone signaling in modulating the exaggerated EPR in hypertension. Effective 108 treatment of EPR overactivity via inhibition of MR/aldosterone signaling may reduce the 109 cardiovascular risks associated with physical activity in hypertension. Future studies are needed 110 to further verify the potential targets affected by MR/aldosterone signaling in hypertension. 111
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